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Background: Inborn errors of immunity (IEI) present with a large phenotypic spectrum of
disease, which can pose diagnostic and therapeutic challenges. Suppressor of cytokine
signaling 1 (SOCS1) is a key negative regulator of cytokine signaling, and has recently
been associated with a novel IEI. Of patients described to date, it is apparent that SOCS1
haploinsufficiency has a pleiotropic effect in humans.
Objective: We sought to investigate whether dysregulation of immune pathways, in
addition to STAT1, play a role in the broad clinical manifestations of SOCS1
haploinsufficiency.
Methods: We assessed impacts of reduced SOCS1 expression across multiple immune
cell pathways utilizing patient cells and CRISPR/Cas9 edited primary human T cells.
Results: SOCS1 haploinsufficiency phenotypes straddled across the International Union
of Immunological Societies classifications of IEI. We found that reduced SOCS1
expression led to dysregulation of multiple intracellular pathways in immune cells.
STAT1 phosphorylation is enhanced, comparably with STAT1 gain-of-function
mutations, and STAT3 phosphorylation is similarly reduced with concurrent reduction of
Th17 cells. Furthermore, reduced SOCS1 E3 ligase function was associated with
increased FAK1 in immune cells, and increased AKT and p70 ribosomal protein S6
kinase phosphorylation. We also found Toll-like receptor responses are increased in
SOCS1 haploinsufficiency patients.org August 2021 | Volume 12 | Article 6803341
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Frontiers in Immunology | www.frontiersin.Conclusions: SOCS1 haploinsufficiency is a pleiotropic monogenic IEI. Dysregulation of
multiple immune cell pathways may explain the variable clinical phenotype associated with
this new condition. Knowledge of these additional dysregulated immune pathways is
important when considering the optimummanagement for SOCS1 haploinsufficient patients.Keywords: inborn error of immunity (IEI), SOCS1, Hyper-IgE syndrome, autoimmunity, genetic pleiotropyINTRODUCTION
Inborn errors of immunity (IEI) encompass rare disorders
with a large phenotypic spectrum. They are increasingly
recognized to display genetic heterogeneity, pleiotropy and
incomplete penetrance (1, 2). This can make the diagnosis and
interpretation of genetic results challenging. To help address these
issues, the International Union of Immunological Societies
(IUIS) proposes a structured approach to classify IEIs into nine
groups based on the predominant clinical and immunological
phenotype (2, 3). A genetic diagnosis is important as it can
facilitate tailored management and personalized therapeutic
strategies (4). Data from patient registries demonstrate a
monogenic diagnosis in one third of European IEI patients
(5, 6). This proportion is likely to increase further with the
expanding number of monogenic IEIs described and increasing
genetic testing (7).
Haploinsufficiency of SOCS1, the gene of suppressor of
cytokine signaling (SOCS) 1, was recently identified as an
autosomal dominant monogenic IEI (8–10). The SOCS protein
family consists of eight members, SOCS 1-7 and the cytokine-
inducible SH2-containing protein (CIS), each characterized by
the presence of an SH2 domain and C-terminal SOCS box
domain (11). SOCS proteins function as important negative
regulators of cytokine signaling, and thus modulate cell
functions. SOCS proteins exert their action by interacting with
Janus kinases (JAKs) and non-receptor tyrosine kinase-2
(TYK2), and surface cytokine receptors, with varying affinities
(11). SOCS1 binds and inhibits the phosphorylation of JAK1/2
and TYK2 (12) thus acting as an intracellular regulator.
Apart from this particular function of SOCS1, other
investigations suppose that SOCS1 impacts on multiple
immune pathways beyond enhanced signal transducer and
activator of transcription (STAT) 1 phosphorylation (13–15)
(Figure 1A). SOCS1 additionally functions as an E3 ligase
substrate (16): SOCS1 binds to ElonginB/C via interaction of
the C-terminal SOCS-box domain, to form a Cullin5 Rbx2 E3
ligase complex (12) (Figure 1B). This complex ubiquitinates
target proteins for proteasomal degradation (12). One such
protein is focal adhesion kinase (FAK) 1, encoded by PTK2
(15). FAK1 is a ubiquitously expressed non-receptor protein
tyrosine kinase which participates in a phosphorylation signaling
pathway downstream of the T-cell receptor, cytokine receptors
and adhesion molecules (17). FAK1 may activate the AKT – p70
ribosomal protein S6 kinase (RPS6K) b1 pathway. Another
target for the SOCS1 E3 ligase is Toll/interleukin-1 receptor
domain-containing adaptor protein (TIRAP), which is anorg 2important adaptor protein involved in Toll-like receptor (TLR)
responses (18).
Although only a limited number of SOCS1+/- individuals have
been identified to date (8–10), it is already apparent that they
show highly variable clinical phenotypes (Table 1). Reported
mutations in SOCS1 are monoallelic, resulting in loss-of-function
of a single allele. Frameshift, truncating and missense mutations
have been identified in three of the five protein domains of
SOCS1 (8–10) (Figure 2A). However, clinical phenotypes lie
across different IUIS groups: immune dysregulation with
multisystem autoimmunity, autoimmune disease such as
systemic lupus erythematosus (SLE), chronic autoimmune
cytopenias and malignancy have all been documented (8–10).
To investigate how these distinct clinical presentations may arise,
we studied the role of SOCS1 in SOCS1+/- patient immune cells
and CRISPR/Cas9- edited primary human T cells.
SOCS1 is expressed in both hematopoietic and non-
hematopoietic cells (19, 20) (Figure 2B), which has important
implications if considering hematopoietic stem cell
transplantation as curative option in IEI patients. Additionally
multiple effects of SOCS1 on intracellular immune pathways are
important to consider when evaluating potential (targeted)
treatments in SOCS1+/- patients.METHODS
Patients, Controls, and PBMC Isolation
Patients and healthy controls were enrolled on protocols
approved by ethics review committees (Dresden: EK
464122017; Cambridge: 13/EE/0305), and provided written
informed consent. Patient and healthy donor peripheral blood
mononuclear cells (PBMC) were isolated by density-gradient
centrifugation using Biocoll separating solution (density 1.077 g/
ml, Biocell). PBMC were resuspended in RPMI culture media
(Gibco), supplemented with glutamate (100m, Life
Technologies), penicillin/streptomycin (100 U/100mg/ml, Life
Technologies) and 10% fetal bovine serum (PAN Biotech).
PBMC Stimulation and FACS Analysis
Intracellular pSTAT1 and total STAT1 kinetics were determined
by FACS analysis. 50 µl whole blood was stimulated according to
BD Phosflow™ T Cell Activation Kit Instruction Manual in
polystyrene round-bottom tubes (Becton Dickinson Falcon).
Blood was stimulated with Imukin® 100ng/ml for 0–180min at
37°C. Erythrocytes were lysed and leucocytes fixed with 1 ml of
pre-warmed 1x lyse/fix buffer. The cells were then permeabilizedAugust 2021 | Volume 12 | Article 680334
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stained with 750 µl stain buffer and incubated for 1 h in the dark
at 4°C with following antibodies: anti-human CD14-FITC (BD
Biosciences 345784), isotype STAT normal mouse IgG2a Alexa
Fluor® 647 (Santa Cruz Biotechnology sc-24637) and Alexa
Fluor® 647 mouse Anti-Stat1 (pY701) (BD Biosciences
612597). For Th1 and Th17 percentages PBMCs were stained
with CD3 – BV605 (Biolegend), CD4 - APC-eFluor780
(eBioscience), CD8 – BV650 (eBioscience), CXCR3 – FITC
(BioLegend), CCR6 – PE-Cy7 (BioLegend), CD45RA – PerCP
(eBioscience) GZMB - e450 (BioLegend), CFSE - Invitrogen. All
data were collected with LSR II (Becton Dickinson) and analyzed
with FlowJo software (Treestar, Ashland, OR, USA).
PBMC Stimulation and
Cytokine Measurement
PBMC (1x106/ml) were left unstimulated or stimulated with
10 ng/ml PMA (Phorbol 12-myristate 13-acetate) and 1µg/ml
Calcium-Ionophore (both Merck KGaA, Darmstadt, Germany)
under addition Brefeldin A (1µl/ml, BD-Biosciences San José,Frontiers in Immunology | www.frontiersin.org 3CA) of for 12h overnight. Cells then were harvested and washed
twice with PBS/1%FCS. For surface staining, cells were incubated
with anti-CD45RO-PE (5µl/test) (Biolegend, San Diego, CA),
anti-CD3-APC (2µl/test), anti-CD4-APC-AlexaFluor750 (5µl/
test) and anti-CD45-Krome Orange (5µl/test) (Beckman
Coulter, Krefeld, Germany) for 30 min at 4°C. After being
washed twice with PBS/1% FCS, cells were fixed and
permeabi l ized with 100µl Cytofix/Cytoperm™ (BD
Biosciences, San José, CA) for 20 min at 4°C and then washed
twice according to the manufacturer’s instructions. For
intracellular staining, cells were incubated with anti-IFNg-FITC
(5µl/test), anti-IL4-PE Cy7 (5µl/test) (both Biolegend) and anti-
IL-17A eFlour 450 (5µl/test) (eBioscience/Thermo Scientific)
and anti-CD4 APC-AlexaFluor750 (2µl/test) (Beckman-
Coulter, Krefeld, Germany) for 45min at 4°C. Cells were
washed twice with Perm/Wash Buffer (BD Biosciences) and
diluted in 500µl PBS/1% FCS. Analysis was performed on a
Navios Flow-Cytometer (Beckman-Coulter-Krefeld). For
measurement of IFN-g and IL-4 production 50,000 T cells per
96 well were stimulated with anti-CD3/CD28 beads (MiltenyiA
B
FIGURE 1 | Summary of SOCS1 actions in T cells. (A) SOCS1 acts on multiple intracellular pathways, both by directly binding and blocking a target (JAK, NF-kB1)
and as a substrate for the formation of an E3 ubiquitin ligase to target proteins for proteasomal degradation (FAK, TIRAP). (B) Simplified schematic of SOCS1 E3
ligase complex assembly with FAK (Focal adhesion kinase) accomplishing ubiquitination of signaling intermediates. AKT, Protein kinase B; Cul, Cullin; FAK, Focal
adhesion kinase; IKK, inhibitor of nuclear factor kappa-B kinase; IRAK, Interleukin-1 receptor associated kinase; JAK, Janus kinase; MyD88, Myeloid differentiation
primary response 88; NEMO, NF-kappa-B essential modulator; NFkB, nuclear factor kappa-light-chain enhancer of activated B cells; PI3K, Phosphoinositide 3
Kinase; Rbx, RING-box protein; RPS6K, Ribosomal protein s6 kinase; SOCS, suppressor of cytokine signaling; STAT, signal transducer and activator of
transcription; TCR, T cell receptor; TIRAP, toll-interleukin 1 receptor (TIR) domain containing adaptor protein; TLR, Toll-like receptor; Ub, Ubiquitin.August 2021 | Volume 12 | Article 680334
TABLE 1 | Clinical phenotypes of SOCS1+/- patients.
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Körholz et al. SOCS1 HaploinsufficiencyBiotec) (ratio cells:beads 1:1 for 24 hours. Supernatants were
then measured using the Meso Scale Discovery V-PLEX
Proinflammatory Panel 1 Human Kit (cat# K15049D).
PBMC Stimulation and Immunoblotting
1x106 PBMCs/ml were incubated in 24 well- plates with 50 ng/ml
of recombinant human IFN-g (PeproTech) for 0 (at rest), 30, 120
and 180 min in complete RPMI medium. To ensure equal
loading, protein concentrations were assessed via Pierce™
BCA Protein Assay Kit (Thermo Scientific). Lysates were
denatured in 1x LDS buffer (Invitrogen) then boiled for 10
mins at 70°C. Lysates were then run on NuPAGE Novex 4-
12% gels (Invitrogen) with Spectra Multicolour Broad Range
Protein Ladder (Invitrogen). Electrophoresis was run a 350A for
1 hour to transfer protein to a PDVF membrane. Membranes
were then blocked with 5% non-fat milk in 1x Tris buffered saline
with 0.1% Tween20 (Sigma) (TBST) for 1 hour at room
temperature. Primary antibodies used were B-actin, Phospho-
STAT1, STAT1, pJAK1, STAT3, pSTAT3, Cyclophilin B,Frontiers in Immunology | www.frontiersin.org 5NFKB1, pAKT, AKT SOCS1, FAK, and JAK2 (all Cell
Signaling). Membranes were incubated overnight with primary
antibodies, then washed 3x 10mins with TBST, before being
incubated with a rabbit HRP-conjugated secondary antibody for
1 hours at room temperature. Membranes were washed a further
3x 10mins with TBST then developed with chemiluminescence
ECL or Femto (Thermo Fisher).
Molecular Genetics Analysis
Genomic DNA (index case and parents) was isolated from
peripheral blood and enriched with a SureSelect Human All
Exon Kit V6 (Agilent technologies) for subsequent Trio-WES on
the Illumina system. Reads were aligned to human genome build
GRCh37/hg19. Sequence reads were called and analyzed
according to an in-house standard operating procedure using
the VarFish platform (21). Variant filtration included filtering by
minor allele frequency, mode of inheritance, functional
prediction and constraint metrics, such as LOEUF score for





FIGURE 2 | SOCS1 tissue expression, genetic and clinical pleiotropy. (A) Schematic of SOCS1 protein showing locations of pathogenic mutations described.
Mutations further investigated here highlighted in red. KIR, Kinase inhibitory region; ESS, Extended SH2 subdomain; SH2, SH2 domain; SOCS box, SOCS box domain
(Uniprot O15524). (B) Heatmap of SOCS1 expression across immune cells and tissues. TPM, transcripts per million. (C) Family trees of two SOCS1+/- kindreds with a
total of three affected individuals. (D) 1Chest radiography and 2computed tomography (CT) scan showing dense consolidation of the entire right lung field with
associated empyema due to bacterial infection in P1 with SOCS1+/-. (E) 1Autoimmune alopecia totalis in the same patient (P1) as well as 2CT scans of widespread
ground glass changes (P2) and 3granulomatous lymphocytic interstitial lung disease next to bronchiectasis (P3) in two unrelated patients with SOCS1
+/- (P2, P3).August 2021 | Volume 12 | Article 680334
Körholz et al. SOCS1 Haploinsufficiencysequencing. The SOCS1 variants have been deposited in ClinVar
under accession numbers VCV000977214 and SCV001653515.1.
Measurement of Interferon Signature
Total RNA was extracted from PBMCs using the RNeasyMini
Kit (Qiagen) followed by DNase I digestion. Gene expression was
determined by quantitative real-time RT-PCR using Taqman
Universal PCRMaster Mix (Applied Biosystems) on an ABI7300
and normalized to the expression of glyceraldehyde-3-phosphate
dehydrogenase and hypoxanthine phosphoribosyltransferase 1
(Hs02800695_m1). For calibration, a calibrator cDNA was
included in each assay. Target genes were analyzed using
predesigned TaqMan probes for IFI44 (Hs00951349_m1),
IFI44L (Hs00915292_m1), IFIT1 (Hs01675197_m1), ISG15
(Hs01921425_s1), RSAD2 (Hs01057264_m1), and SIGLEC1
(Hs00988063_m1). Oligonucleotides used for quantitative RT-
PCR of GAPDH were for-GAAGGTGAAGGTCGGAGTC, rev-
GAAGATGGTGATGGGATTTC, and FAM-CAAGCTTC
CCGTTCTCAGCC-TAMRA. The IFN score was calculated as
previously described by Wolf et al. (23).
Magnetic Cell Separation
Human blood from healthy controls or SOCS-1 haploinsufficient
patients was collected and fractionated for peripheral blood
mononuclear cells (PBMC) by Pancoll (P04-60500, PAN-
Biotech). PBMC were proceeded with human Pan Monocyte
Isolation Kit (130-096-537, Miltenyi Biotec) following
manufacture’s procedure. Magnetic microbeads-stained PBMC
were subjected to autoMACS Pro Sparator (Miltenyi Biotec) for
un-touched monocyte enrichment. 50,000 per well of sorted pan-
monocytes were seeded into 96-well plate and cultured with
RPMI-1640 medium (R2405-500ML, Sigma-Aldrich) + 5%
Human AB se rum (P30-2501 , PAN-B io t e ch ) fo r
further stimulation.
Pan-Monocytes Stimulation
Sorted pan-monocytes from healthy controls and SOCS-1
haploinsufficient patients were left untreated (UT), or
stimulated with different TLR ligands. Briefly, TLR stimulants
used were: Pam3CSK4 (tlrl-pms) TLR2, LPS (tlrl-peklps) TLR4,
Flagellin (tlrl-pafla) TLR5, R837 (tlrl-imqs) TLR7, R848 (tlrl-
r848) TLR7/8, TL8-506 (tlrl-tl8506) TLR8, and ODN 2216 (tlrl-
2216) TLR9 were all from Invivogen. RIBOXXOL (A-00102,
Riboxx) is a double-stranded RNA duplex which stimulates
TLR3. Pan-monocytes were stimulated with RIBOXXOL at
2 ng/ml, LPS at 0.5 µg/ml, ODN 2216 at 1 µM, and Flagellin,
R837, R848, TL8-506 all at 1 µg/ml for 20 hours.
Cytokine Bead Arrays
Cytokine Bead Arrays (CBA) were performed by using
LEGENDplex human anti-virus response panels 13-plex
(740390, Biolegend). After stimulation, supernatants were
collected by centrifugation at 800G for 5 minutes, and then
subjected to CBA 13-plex panels following the manufacture’s
procedure. Levels of IL-1b, IL-6, TNF-⍺, IP-10, IL-29(IFN-l1),
IL-8, IL-12p70, IFN-a2, IL-28A/B(IFN-l2/3), GM-CSF, IFN-b,
IL-10, and IFN-g were measured simultaneously by MACSQuantFrontiers in Immunology | www.frontiersin.org 6analyzer 10 (Miltenyi Biotec). FCS files were further analyzed by
LEGENDplex data analysis software version 8.0 (Biolegend).
Cytokine Heatmap Hierarchical Clustering
Cytokine results were transformed by [log10(original cytokine
concentration x) – row means (mean value of each cytokine after
log10 transformation) of log10(x)]. Heatmap was constructed of
row Z scores and then clustered by average linkage with
Euclidean distance measurement method. Heatmap was
generated using heatmap.2 in R studio.
Autoantibody Testing
To look for the induction of different cell, organ and tissue specific
autoantibodies (AAB) as well as ABs directed against highly
conserved non-organ specific autoantigens (AAGs) we used a
broad panel of AAB test methods (see Table 1). Different antigenic
targets were used by indirect immunofluorescence tests
(Euroimmun AG, Lübeck, Germany; GA Generic Assays,
Dahlewitz, Germany) to identify non-organ specific AAB (HEp-
2 cell assay: antinuclear antibodies, anticytoplacmic antibodies)
(24), antineutrophil cytoplasmic antibodies (human neutrophile
granulocytes), endomysial antibodies (primate intestine), AABs
characteristic for autoimmune liver diseases (rat organ kryostat
sections: LKM, AMA, SMA), AABs specific for autoimmune
endocrine diseases (primate endocrine organ sections: adrenal
gland, parathyroid gland, pancreas, ovary and testis sections),
anti-glomerular basement antibodies (kidney sections) and
AABs specific for kidney and autoimmune neurologic diseases
(HEK293 cells specific transfected with target autoantigens like
NMDA receptor). Furthermore, immunoassays for the detection
of AABs directed against highly purified or recombinant target
antigens such as line immunoassays (D-tec s.a., Moons, Belgium;
GAGeneric Assay, Dahlewitz, Germany; ravo Diagnostika GmbH,
Freiburg, Germany), enzyme immunoassays (GA Generic Assays
and Medipan GmbH, Dahlewitz, Germany; AESCU Group
GmbH & Ko KG, Wendelsheim, Germany; Orgentec
Diagnostika GmbH, Mainz, Germany), chemiluminescence
immunoassay (Inova Diagnostics, Inc., San Diego, USA) and
radioimmunoassays (DLD Diagnostika GmbH, Hamburg,
Germany) were used to identify AABs specific for autoimmune
liver (LKM-1, LC1, SLA, actin, gp210, sp100, GBM, MPO),
neurologic (Ma1, Ma2, Amphiphysin, CV2, HuD, GAD65,
SOX1, Zic4, DNER, AchR, MuSk, VGCC, VGKC, 10 different
gangliosides), endocrine (IFA, H+K+-ATPase, GAD, IA2, INS,
ZnT8, TG, TPO, 21H), kidney (GBM,MPO, PR3), gastrointestinal
(GTG, GDP, ASCA, GP2) as well as systemic autoimmune
diseases (MPO, PR3, CCP, MCV, CEP-1, RA33, RF, C1q, 5
different aPL).
Primary Human CD4+ T Cell CRISPR/Cas9
Healthy control CD4+ T cells were isolated from fresh blood
PBMCs using human CD4+ T cell isolation Kit (130-096-533,
Miltenyi Biotec) according to the manufacturer’s instructions.
5x106 CD4+ T cells were electroporated using a Nucleofector 2b
program V024 (resting T cells) (Lonza). SOCS1 crRNA guide:
CGGCGUGCGAACGGAAUGUGGUUUUAGAGCUAUGCU
was combined to form sgRNA heteroduplexes with Alt-R®August 2021 | Volume 12 | Article 680334
Körholz et al. SOCS1 HaploinsufficiencyCRISPR-Cas9 tracrRNA (1072534, Integrated DNA
Technologies), then with Alt-R® CRISPR-Cas9 S.p. Cas9 D10A
Nickase V3 (1081059, Integrated DNA Technologies) for
electroporation. Negative control (Alt-R® CRISPR-Cas9
Negative Control crRNA). Following electroporation cells were
rested for 48 hours in antibiotic free media before transfer to
complete RPMI.RESULTS
Clinical Presentation and
Immunophenotype Are Heterogenous in
SOCS1 Haploinsufficient Patients
SOCS1 haploinsufficient patients are known to present with
variable phenotypes with incomplete penetrance. SOCS1
patients may present with Hyper IgE-like syndrome (HIES)
with eczema and purulent infections, P1 had a HIES score of
48 (25) (Table 1, Table S2 and Figures 2C, D), eosinophilic
allergic alveolitis (EAA) in P2 (Table 1 and Figures 2C, E) as
well as common variable immunodeficiency (CVID)-like
phenotype with hypogammaglobulinemia, T-cell lymphopenia
and granulomatous lymphocytic interstitial lung disease
(GLILD) in P3 (Table 1, Table S1 and Figures 2C, E).
Autoimmune and autoinflammatory features are frequent in
almost all patients (Table 1, Figure 2E). These variable
phenotypes with autoimmunity are evident from the overview
of SOCS1 haploinsufficiency phenotypes (Table 1) which
demonstrates the clinical spectrum spans from autoimmunity
to infections and malignancy.
Immunophenotyping results from SOCS1+/- patients are
variable, with hypogammaglobulinemia and a B-cell-
maturation deficiency described in one patient. T-cell counts
and subpopulations were normal in one kindred, P3, then
following steroid treatment for lung disease, showed reduced T
cell numbers with normal subpopulations. T-cell proliferation in
response to anti-CD3/CD28 stimulation was normal, as
described previously (10), but we observed increased cell
division in response to interleukin 7 in SOCS1 knockdown
CD4+ T cells derived from healthy donors (Figure S7).
SOCS1 haploinsufficiency impacts on intracellular JAK/STAT
signaling of patient immune cells.
To investigate the clinical overlap of P1 with the Hyper IgE
Syndrome as STAT3LOF we explored similarities and differences
in cytokine signaling via the JAK/STAT pathway. In SOCS1+/-
patients’ T cells we observed reduced STAT3 phosphorylation,
and a decrease in Th17 cells as well as IL-17 production
(Figures 3A, B). SOCS1+/- patients also exhibited enhanced
Th1 polarization of CD4+ T cells and increased production of
interferon-gamma (IFNg) (Figure 3A). Th1*, IL-4 production,
and regulatory T cells were also reduced in SOCS1+/- patients
(Figure S1 and Figure 3C).
Investigation of peripheral blood mononuclear cells (PBMCs),
monocytes and B-lymphoblastoid cell lines (BLCLs) derived from
SOCS+/- patients (P1, P2 and P3) showed increased STAT1
phosphorylation, reminiscent of STAT1 gain-of-function (GOF)Frontiers in Immunology | www.frontiersin.org 7patients (Figures 3D, E, G). These observations could be
demonstrated in western blots of PBMCs and BLCLs, as well as
and in phospho-flow assays on Monocytes. pSTAT1 expression
was not only increased but seemed also prolonged compared to
healthy controls and STAT1GOF patients. In contrast to STAT1GOF
patients, SOCS1+/- patients showed increased and prolonged JAK1
phosphorylation in BLCLs (Figure 3F), which is consistent with
the expected impact of SOCS1+/-, but distinct from STAT1GOF.
However, although JAK/STAT signaling seems to be
hyperactivated in SOCS1+/- patients comparable to STAT1GOF, a
transcriptional type I interferon signature was not prominent in
P1 and P2 (Figure S2). Thus, perturbations in JAK – STAT1
signaling are found in SOCS1 haploinsufficient patients.
SOCS1 Haploinsufficiency Disrupts
Proteasomal Degradation via E3
Ligase Functions
Apart from JAK/STAT signaling, SOCS1 is an important
regulator in multiple other intracellular pathways (Figure 1A).
We therefore investigated how SOCS1 haploinsufficiency in
humans influenced other intracellular signaling pathways.
Patients’ PBMCs and T-cell blasts were investigated for protein
expression in the FAK1-AKT-RPS6K pathway via western blots.
In SOCS1+/- patient cells we found FAK1 levels to be increased
along with enhanced phosphorylated AKT and RPS6K (data
shown for PBMCs in Figures 3I, J), consistent with an increased
activity in the FAK1 – AKT – RPS6K pathway. To confirm these
results, we analyzed protein expression in SOCS1 knockdown
CD4+ T cells. Similarly we could observe increased FAK and
JAK2 expression as well as increased AKT phosphorylation in
this healthy control CD4+ T cell SOCS1 knockdown model
(Figures S5, S6).
In the next step, we investigated TLR responses in SOCS+/-
patients’ monocytes. Notably, we observed enhanced cytokine
responses to a variety of TLR ligands (TLR2-5 and TLR 7-9) in
SOCS1+/- patients (Figure 3H). Pre-incubation and activation of
monocytes with IFN-g further increased differences in cytokine
production between SOCS+/- patients and healthy controls,
consistent with the induction of a hyperactivated state
(Figure S8).DISCUSSION
SOCS1 haploinsufficiency has recently been described as a
pleiotropic IEI with variable penetrance (8–10). Overall, the
presentation of human SOCS1+/- appears to be predominantly
autoimmunity as opposed to infection (Table 1). Additionally,
malignant disease such as Hodgkin’s lymphoma has been observed
in one SOCS1+/- patient (10). According to the national cancer
institute, somatic SOCS1mutations could be identified in several B
cell malignancies (26). Thus in the broad phenotypic spectrum of
SOCS1 haploinsufficiency, malignancy seems to be another
complication treating physicians have to be aware of.
Indeed, the phenotypic spectrum exceeds distinct
characterizations of other monogenic IEIs characterized by theAugust 2021 | Volume 12 | Article 680334
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syndrome and severe atopy phenotype in the first kindred
reported here has additional clinical overlaps with STAT3LOF
patients. Similar to STAT3LOF patients (27), we could observe
reduced pSTAT3 expression and reduced Th17 cells in SOCS1+/-
patients. Complications like severe bacterial pneumonia,
organizing pneumonia and allergic asthma may point towards
a role of SOCS1 in local immunity, e.g. in lung tissue. In patients
with severe asthma, decreased SOCS1 expression correlated with
eosinophilia and Th2-driven inflammation (28). Furthermore,Frontiers in Immunology | www.frontiersin.org 8mice with a selective knockout of the nuclear localization
sequence (NLS) of SOCS1 presented with low-grade
pulmonary inflammation and an increase in Th2-type
cytokines (13). In our patients Th2-type cytokines in CD4+ T
cells were not elevated as compared to healthy controls,
emphasizing the importance of local effects such as
inflammation of SOCS1 in different tissues.
Multiple autoimmune manifestations are reminiscent of other
IEIs such as STAT1GOF, a monogenic IEI characterized by a








FIGURE 3 | Impact of SOCS1 haploinsufficiency on immunophenotype, JAK/STAT signaling as compared to STATGOF and intracellular signaling pathways beyond
JAK/STAT. (A) Reduced pSTAT3 in SOCS1+/- T cell blasts following IL-6 stimulation, reduced Th17 (CD3+CD4+CXCR3-CCR6+) cells in SOCS1+/-patients,
increased proportions of Th1 (CD3+CD4+CXCR3+CCR6-) cells in SOCS1+/- patients, and increased IFN-g from CD4+ T cells in response to anti-CD3/CD28
stimulation and compared with healthy controls. (B) FACS plots of IL-17 expression in fresh T cells (CD3+) of P1 and P2 compared to a healthy control. (C) FACS
plots of regulatory T cells (Tregs) from frozen PBMCs of P1 and P2 and fresh blood of P3 as well as three representative plots from healthy controls (published in
Supplementary Material of 8). (D) Graphical expression of immunoblots of pSTAT1 from a time-course of IFN-g stimulated PBMCs of SOCS1+/- patients and a
STAT1GOF patient (p.(Pro293Leu), located in the Coiled coil domain of STAT1). Error bars: Mean±S.E.M. (E) Immunoblots of pSTAT1 and STAT1 from an IFN-g
stimulation time-course from BLCLs from SOCS1+/- and STAT1GOF patients. (F) Immunoblots of pJAK1 from an IFN-g stimulation time-course from BLCLs from
SOCS1+/- and STAT1GOF patients. (G) Mean fluorescence intensity time-course of pSTAT1 in monocytes from patients with SOCS1+/- and STAT1GOF. (H) Heatmap
and hierarchical clustering of normalized cytokine production [log10(original cytokine concentration x) – row means (mean value of each cytokine after log10
transformation) of log10(x)] in response to TLR ligands (TLR 2-5 and TLR 7-9) in monocytes of SOCS1+/- patients and healthy controls. (I) Quantifications of
immunoblots of IFN-g 20ng/ml stimulation time-course in PBMCs for SOCS1, FAK and pAKT in P1 and P2 compared to two matched healthy controls.
(J) Representative immunoblot of IFN-g stimulation time-course in PBMCs for FAK and AKT in a SOCS1+/- patient.August 2021 | Volume 12 | Article 680334
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candidiasis (CMC) (29). Unlike in STAT1GOF and STAT3LOF
patients, CMC has not been observed in SOCS1+/- patients
although Th17 cells and IL-17 cytokine production in
SOCS1+/- patients were reduced. Delimiting the immunological
phenotype of SOCS1+/- patients from STAT1GOF patients, we
could observe some immunological differences. Unlike in
STAT1GOF patients T-cell proliferation in response to anti-
CD3/CD28 stimulation was normal in T cells of SOCS1+/-
patients. Additionally regulatory T cells are reduced in most
SOCS1+/- patients, unlike in STAT1GOF (30). Moreover, type I
IFN-signature was not elevated in our own SOCS1+/- patients.
This stands in contrast to STAT1GOF patients (31) and may be
due to lack of intrinsic overactivation of the STAT1-interferon
pathway. However, triggers like infections may easily tip this
balance, as reported in two previously reported SOCS1+/- patients
with autoimmune cytopenia (9).
The SOCS1 protein with its subdomains acts not only on JAK/
STAT signaling but is also an important regulator in other
intracellular signaling pathways. As SOCS1 functions as an E3
ligase substrate it is also involved in FAK-AKT-RS6K and TLR
signaling. We demonstrated that SOCS1+/- patient cells showed an
increased activity in the FAK – AKT – RS6K pathway further
explaining the accumulation of autoimmunity. Whilst reduced
SOCS1 appears associated with increased FAK1, we observed a
greater increase in P1 compared to P2 (Figure 3I). Although FAK
expression has not been reported to be influenced by age,
additional elements of the AKT pathway have been (32).
Therefore in SOCS1 haploinsufficient patients age, or the specific
impact of variants, may influence FAK expression. Further
investigation in SOCS1 haploinsufficient patient over a range of
ages and variants are warranted to confirm these observations.
Investigating TLR responses in SOCS+/- patients, we observed
enhanced cytokine responses. This observation is supported by
previous investigations which identified SOCS1 as an important
target in the negative regulation of TCR signaling and which
demonstrated that the ablation of SOCS1 in human T cells
enhances T cell proliferation (33). These increased even further
by stimulation with IFN-g imitating an immune response in a
hyperactivated state. This in vitro observation may mimic the
observed infection-induced autoimmune cytopenias in SOCS+/-
patients (9, 10). Disruption of intracellular signaling via SOCS1
in these multiple intracellular pathways may partially explain the
spectrum of clinical diversity in SOCS1+/- patients.
Both PBMCs and T cell blasts of patients P1 and P2 with the
variant Y64X showed reduced SOCS1 expression to below 50% of
controls (Figure 3J and Figure S4), whilst expression of SOCS1
protein was still evident in Y64X patient derived BLCLs (Figure
S3). Regulation of SOCS1 is achieved by several mechanisms in
vivo, including by translation of an upstream open reading frame
(uORF) from an alternative translation start site in the SOCS1
mRNA (34, 35). The variant Y64X may still allow translation of
this repressive uORF from the mutated SOCS1 allele which may,
in certain cell types and states, result in repression of SOCS1 below
50%. Determining how, and if, this regulatory mechanism is
effecting SOCS1 expression in patients with pathogenic SOCS1
variants will further elucidate this interested mechanism ofFrontiers in Immunology | www.frontiersin.org 9translational regulation and how it may play a role in the
clinical disease severity of SOCS1-related diseases.
In summary, reduced SOCS1 shows clinical overlaps with
different monogenic IEIs, such as STAT3LOF and STAT1GOF. On
a cellular level it is associated with increased JAK – STAT1
signaling, and reduction of the SOCS1 E3 ligase function, which
may account for the dysregulation of multiple additional
immune pathways. These multiple effects are important to
consider when treating SOCS1+/- patients. JAK inhibitors have
been shown in vitro to reduce exuberant STAT1 phosphorylation
seen in SOCS1+/- patients (10). Potential therapeutic efficacy of
JAK inhibitors warrants further clinical investigation, but may
not fully suppress the additional hyperactive pathways present in
SOCS1+/-. Treatment of autoimmunity associated with SOCS1+/-
may therefore require a broader immunosuppressive approach.
Whilst hematopoietic stem cell transplantation may offer a
curative treatment for severe SOCS1+/- disease to prevent organ
damage through chronic infections and/or autoimmunity, its
potential limitations need to be considered due to the non-
hematopoietic expression of SOCS1. There is need for the
co l l ec t ion and study of larger cohort s o f SOCS1
haploinsufficient patients to confirm and further study the
observations we present here of the multiple immune pathway
dysregulation evident in this patient group.DATA AVAILABILITY STATEMENT
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